Share Twitter LinkedIn Facebook Email Isaac Israel CEO @isaac2199 Of Kitov Pharmaceuticals Discusses CM-24 Monoclonal Antibody: Plan To Initiate A Clinical Trial In Combination With Nivolumab, Initially Selecting NSCLC Patients.
VIDEO: iTeos and GSK’s TIGIT Combination Therapy Shows Significant Promise at ESMO 2024 Non-Small Cell Lung Cancer 2 Mins Read
VIDEO: FDA Approves Atezolizumab / Tecentriq Hybreza For Subcutaneous PD-(L)1 Cancer Immunotherapy in NSCLC Kidney 4 Mins Read